Virus Baltimore classification Kinase inhibitors showing antiviral activity(potential kinase targets)
SARS-CoV-2 Group IV, positive sense single-stranded RNA virus imatinib
(unpublished; preprint: https://www.biorxiv.org/content/10.1101/2020.03.25.008482v2.full)
abemaciclib, gilteritinib, osimertinib
(unpublished; preprint:
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v3.full.pdf)
SARS-CoV Group IV, positive sense single-stranded RNA virus imatinib, dasatinib, nilotinib (ABL2)
(27) (29)
MERS-CoV Group IV, positive sense single-stranded RNA virus imatinib, dasatinib (ABL2) (27)
saracatinib (LYN, FYN) (33)
sorafenib (RAF) (68)
Dengue Group IV, positive sense single-stranded RNA virus dasatinib, saracatinib (SRC, FYN) (34) (35) (36)
sunitinib, erlotinib (AAK1, GAK, AXL, KIT, RET) (46)
Hepatitis C Group IV, positive sense single-stranded RNA virus sunitinib, erlotinib (AAK1, GAK) (41) (42)
gefitinib, erlotinib (EGFR) (59) ((56) (57)
West Nile Group IV, positive sense single-stranded RNA virus sunitinib, erlotinib (46)
Zika Group IV, positive sense single-stranded RNA virus sunitinib, erlotinib (46)
Ebola Group V, negative sense single-stranded RNA virus nilotinib (ABL1) (24)
Influenza A Group V, negative sense single-stranded RNA virus alvocidib (CDK9)
Human cytomegalovirus Group 1, double-stranded DNA virus gefitinib, erlotinib (EGFR) (59) (57) (56)
Vaccinia Group 1, double-stranded DNA virus imatinib (ABL) (25)
Herpes simplex type 1 Group 1, double-stranded DNA virus palbociclib (CDK6) (62)